<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Akibah Health Corporation

    Akibah Health Corporation

    GluCase is an all-in-one diabetes management system that seamlessly integrates a g...

    GluCase is an all-in-one diabetes management sy...

    Amount Raised:    $38,481.00
    Fundraising Status:    EC
    Filing Type:    CF
    Galmed Pharmaceuticals Ltd.

    Galmed Pharmaceuticals Ltd.

    Galmed is a clinical-stage biopharmaceutical company focused on the development of...

    Galmed is a clinical-stage biopharmaceutical co...

    Filing Type:    PU
    Alector, Inc.

    Alector, Inc.

    We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a n...

    We are a clinical stage biopharmaceutical compa...

    Filing Type:    PU
    OraSure Technologies, Inc.

    OraSure Technologies, Inc.

    OraSure Technologies is empowering the global community to improve health and well...

    OraSure Technologies is empowering the global c...

    Filing Type:    PU
    Bio-Techne Corp

    Bio-Techne Corp

    Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of h...

    Bio-Techne Corporation (NASDAQ: TECH) is a lead...

    Filing Type:    PU
    Merit Medical Systems, Inc.

    Merit Medical Systems, Inc.

    Founded in 1987, Merit Medical set out to build the world’s most customer-focuse...

    Founded in 1987, Merit Medical set out to build...

    Filing Type:    PU
    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc.

    SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company focused...

    SELLAS Life Sciences Group, Inc. is a late-stag...

    Filing Type:    PU
    Merck KGaA

    Merck KGaA

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...

    Merck KGaA, Darmstadt, Germany, a leading scien...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Adaptimmune Therapeutics PLC

    Adaptimmune Therapeutics PLC

    Adaptimmune is a leader in TCR T-cell therapy, focused on developing novel cancer ...

    Adaptimmune is a leader in TCR T-cell therapy, ...

    Filing Type:    PU
    FibroGen, Inc

    FibroGen, Inc

    FibroGen, Inc. is a leading science-based biopharmaceutical company discovering an...

    FibroGen, Inc. is a leading science-based bioph...

    Filing Type:    PU
    CytoDyn Inc.

    CytoDyn Inc.

    CytoDyn is a publicly traded late stage biotechnology company developing innovativ...

    CytoDyn is a publicly traded late stage biotech...

    Filing Type:    PU
    ©2025 National Investor Network. All Rights Reserved.